SLANSKY RICHARD B 4

What Happened Richard B. Slansky, Chief Financial Officer of Genenta Science S.p.A. (GNTA), was granted a derivative award covering 80,000 shares on March 30, 2026. The grant is reported as acquired at $0.00 (total reported cash paid = $0). This is an equity award (stock options per filing footnote) rather than a market purchase or sale.

Key Details

• Transaction date: 2026-03-30; reported on Form 4 filed 2026-04-01 (appears timely).
• Transaction type: Grant / award of a derivative (stock options) — 80,000 shares @ $0.00.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: F1 — the options vest in equal monthly installments over three years beginning March 30, 2026.
• No indication of immediate sale or tax-withholding reported in this filing.

Context This is a standard executive equity grant intended to align management incentives with shareholders; it does not represent an open-market purchase or sale. For retail investors, grants signal compensation/retention actions by the company but do not by themselves indicate the insider’s view on short-term stock moves.